Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Feb 01, 2024 1:09pm

115 Views

Post# 35857488

"Thrilled": The Path... The Daisy Chain... The Way...

Nothing like watchng a bunch of whiners on Stockhouse complain who don't propose a viable alternative after Ronnie Miller has evaluated the alternatives and is "thrilled" about this daisy chain!

"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business..." news release

The path to a long-term sustainable business is key.

The merger provides capital and internal capabilities from AEZS to "fully support" CZO's near-term revenue generatng development programs.

Gilles Gagnon, Chief Executive Officer of Ceapro: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..." news release

With financing and internal capabilities in place you can see why Ronnie Miller is "thrilled", Gilles is 'excited' and the Chair of AEZS is 'compelled'. Gilles is on the insideof both CZO and AEZS and knows the deals, etc., being worked on. Gilles wants CZO's pipeline on NASDAQ now for a reason. Given H.C. Wainwright's US$15 target and that it is a merger of equals the target valuation of this deal is arguably C$200 million or ~$1.25 per current CZO share.

The path,
the daisy chain of events that will define this merger...

AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision

Image result for daisy chain fireworks